Yang J, Chen G, Wang R, Song C, Yi H
Cancer Immunol Immunother. 2025; 74(5):146.
PMID: 40088262
DOI: 10.1007/s00262-024-03879-z.
Malikova I, Worth A, Aliyeva D, Khassenova M, Kriajevska M, Tulchinsky E
Cell Death Dis. 2025; 16(1):155.
PMID: 40044635
PMC: 11883011.
DOI: 10.1038/s41419-025-07480-9.
Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L
Signal Transduct Target Ther. 2025; 10(1):37.
PMID: 39924521
PMC: 11808115.
DOI: 10.1038/s41392-024-02121-7.
Liu Z, Li Y, Ren Y, Chen J, Weng S, Zhou Z
Aging Cell. 2025; 24(2):e14467.
PMID: 39748782
PMC: 11822654.
DOI: 10.1111/acel.14467.
Crossman B, Harmon R, Kostecki K, McDaniel N, Iida M, Corday L
J Clin Med. 2024; 13(20).
PMID: 39457986
PMC: 11508784.
DOI: 10.3390/jcm13206036.
Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target.
Pidkovka N, Belkhiri A
Front Oncol. 2023; 13:1079041.
PMID: 37469409
PMC: 10353021.
DOI: 10.3389/fonc.2023.1079041.
Advances in Lung Cancer Treatment Using Nanomedicines.
Sharma A, Shambhwani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M
ACS Omega. 2023; 8(1):10-41.
PMID: 36643475
PMC: 9835549.
DOI: 10.1021/acsomega.2c04078.
AXL-Receptor Targeted 14FN3 Based Single Domain Proteins (Pronectins™) from 3 Synthetic Human Libraries as Components for Exploring Novel Bispecific Constructs against Solid Tumors.
Hokanson C, Zacco E, Cappuccilli G, Odineca T, Crea R
Biomedicines. 2022; 10(12).
PMID: 36551940
PMC: 9775294.
DOI: 10.3390/biomedicines10123184.
Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation.
Poswiata A, Kozik K, Miaczynska M, Zdzalik-Bielecka D
Cell Mol Life Sci. 2022; 79(6):316.
PMID: 35622156
PMC: 9135597.
DOI: 10.1007/s00018-022-04312-3.
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Engelsen A, Lotsberg M, Abou Khouzam R, Thiery J, Lorens J, Chouaib S
Front Immunol. 2022; 13:869676.
PMID: 35572601
PMC: 9092944.
DOI: 10.3389/fimmu.2022.869676.
Efficacy of newly discovered DNA aptamers targeting AXL in a lung cancer cell with acquired resistance to Erlotinib.
Hwang J, Hur J, Kim Y, Im J, Jin S, Ryu S
Transl Cancer Res. 2022; 10(2):1025-1033.
PMID: 35116429
PMC: 8798984.
DOI: 10.21037/tcr-20-2447.
Multi-target drug with potential applications: violacein in the spotlight.
Duran N, Nakazato G, Duran M, Berti I, Castro G, Stanisic D
World J Microbiol Biotechnol. 2021; 37(9):151.
PMID: 34398340
DOI: 10.1007/s11274-021-03120-4.
AXL, an Important Host Factor for DENV and ZIKV Replication.
Xie S, Zhang H, Liang Z, Yang X, Cao R
Front Cell Infect Microbiol. 2021; 11:575346.
PMID: 33954117
PMC: 8092360.
DOI: 10.3389/fcimb.2021.575346.
Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10.
Maimon A, Levi-Yahid V, Ben-Meir K, Halpern A, Talmi Z, Priya S
J Clin Invest. 2021; 131(10).
PMID: 33848267
PMC: 8121514.
DOI: 10.1172/JCI126089.
MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
Chen C, Liu Y
Pharmaceuticals (Basel). 2021; 14(2).
PMID: 33562150
PMC: 7915726.
DOI: 10.3390/ph14020130.
Experimental and bioinformatics considerations in cancer application of single cell genomics.
Juan Tan J, Kong S, Tai J, Poh H, Yao F, Sia Y
Comput Struct Biotechnol J. 2021; 19:343-354.
PMID: 33489004
PMC: 7788095.
DOI: 10.1016/j.csbj.2020.12.021.
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity.
Rios-Doria J, Favata M, Lasky K, Feldman P, Lo Y, Yang G
Front Oncol. 2021; 10:598477.
PMID: 33425754
PMC: 7793849.
DOI: 10.3389/fonc.2020.598477.
Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer.
Wang T, Wu C, Huang K, Leu Y, Yang S, Chen C
Cancers (Basel). 2021; 13(1).
PMID: 33396393
PMC: 7795510.
DOI: 10.3390/cancers13010111.
AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors.
Landers S, Bhalla A, Ma X, Lusby K, Ingram D, Al Sannaa G
J Cancer Sci Clin Ther. 2020; 4(4):511-525.
PMID: 33283192
PMC: 7717506.
DOI: 10.26502/jcsct.5079091.
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
Falcone I, Conciatori F, Bazzichetto C, Bria E, Carbognin L, Malaguti P
Int J Mol Sci. 2020; 21(22).
PMID: 33182542
PMC: 7696061.
DOI: 10.3390/ijms21228419.